As Vice President, Head of Corporate Strategy and Program Leadership, Shiva leads corporate development and portfolio strategy, competitive intelligence, and partnerships, helping shape the company’s growth, pipeline prioritization, clinical program leadership, and external engagement. She brings over 13 years of biopharma experience spanning oncology drug development, strategy development and execution, and alliance and program leadership across large and small, private and public biotech and pharmaceutical companies.

Prior to joining Marengo, Shiva held leadership roles at AstraZeneca, where she led Early Oncology R&D portfolio strategy and established the “Partner of Choice” initiative, building strategic collaborations with leading global academic institutions. She played a key role in shaping investments across cell therapy, immuno-oncology, immune engagers, and antibody-drug conjugates, contributing to the advancement of AstraZeneca’s oncology pipeline. Prior to the AstraZeneca merger, at MedImmune she led global program teams from research through clinical proof of concept and transition into late-stage development. Her large pharma experience was complemented by earlier roles in small biotech, where she supported operational execution and business development during critical growth phases. She began her career at STC Biologics and Nant entities, gaining broad experience working with executive leadership across operations, business development, and program and alliance management.

Shiva earned her BA and MA in Biochemistry and Molecular Biology from Boston University, where she also developed strong scientific and benchtop expertise through industry internships. She holds a PhD in Molecular Pharmacology and Oncology from New York University and an MBA from Babson College. Her work has been recognized with multiple leadership and CEO awards.